

2025 Brazilian Evidence-based Guideline on the Management of Obesity and Prevention of Cardiovascular Disease and Obesity-Associated Complications: A Position Statement by Five Medical Societies

Development: Associação Brasileira para o Estudo da Obesidade e da Síndrome Metabólica (ABESO), Sociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Cardiologia (SBC), Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) e Academia Brasileira do Sono (ABS)

Guideline Authors: José Francisco Kerr Saraiva,¹ Cynthia M. Valerio,² Fabiana H. Rached,³ Simone Van de Sande-Lee,⁴ Viviane Z. Rocha Giraldez,³ Fernando Valente,⁵ Luciano F. Drager,³ Bruno Halpern,⁶ Wellington S. da Silva Junior,⁷ Fabio R. Trujillo,^{8,9} Neuton Dornellas,¹⁰ Ruy Lyra da Silva Filho,¹¹ João Eduardo N. Salles,¹² Marcelo H. V. Assad,¹³ Marcio C. Mancini,^{14,15} Paulo A. C. Miranda,^{16,17} Rodrigo O. Moreira,¹⁸ Rodrigo N. Lamounier,^{19,20} Sergio E. Kaiser,²¹ Marcello C. Bertoluci²²

Pontifícia Universidade Católica de Campinas,¹ Campinas, SP – Brazil

Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione (IEDE-RJ),² Rio de Janeiro, RJ – Brazil

Instituto do Coração (Incor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP),³ São Paulo, SP – Brazil

Universidade Federal de Santa Catarina (UFSC),⁴ Florianópolis, SC – Brazil

Faculdade de Medicina do ABC,⁵ São Paulo, SP – Brazil

Centro de Controle de Peso do Hospital 9 de Julho,⁶ São Paulo, SP – Brazil

Universidade Federal do Maranhão (UFMA),⁷ São Luís, MA – Brazil

Instituição Centro de Diabetes e Endocrinologia da Bahia (CEDEBA),⁸ Salvador, BA – Brazil

Hospital da Obesidade,⁹ Salvador, BA – Brazil

Corpo de Bombeiros Militar do Distrito Federal,¹⁰ DF – Brazil

Universidade Federal de Pernambuco (UFPE),¹¹ Recife, PE – Brazil

Faculdade de Ciências Médicas da Santa Casa de São Paulo,¹² São Paulo, SP – Brazil

Instituto Nacional de Cardiologia (INC),¹³ Rio de Janeiro, RJ – Brazil

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (USP),¹⁴ São Paulo, SP – Brazil

Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (ABESO),¹⁵ São Paulo, SP – Brazil

Santa Casa de Belo Horizonte,¹⁶ Belo Horizonte, MG – Brazil

Rede Mater Dei de Saúde,¹⁷ Belo Horizonte, MG – Brazil

Centro Universitário Presidente Antônio Carlos (UNIPAC),¹⁸ Juiz de Fora, MG – Brazil

Universidade Federal de Minas Gerais (UFMG),¹⁹ Belo Horizonte, MG – Brazil

Centro de Diabetes de Belo Horizonte (CDBH),²⁰ Belo Horizonte, MG – Brazil

Universidade estadual do Rio de Janeiro (UERJ),²¹ Rio de Janeiro, RJ – Brazil

Universidade Federal do Rio Grande do Sul (UFRGS),²² Porto Alegre, RS – Brazil

SBC Clinical Practice Guidelines Committee: Pedro Gabriel Melo de Barros e Silva (Coordenador), Helena Cramer Veiga Rey, Humberto Graner Moreira, José Augusto Soares Barreto Filho, Nadine Oliveira Clausell – Period 2025-2027

How to cite this Guideline Saraiva JFK, Valerio CM, Rached FH, van de Sande-Lee S, Giraldez VZR, Valente F, et al. 2025 Brazilian Evidence-based Guideline on the Management of Obesity and Prevention of Cardiovascular Disease and Obesity-Associated Complications: A Position Statement by Five Medical Societies. Arq Bras Cardiol. 2025; 122(9):e20250621

Guidelines

Note: These guidelines are for information purposes and should not replace the clinical judgment of a physician, who must ultimately determine the appropriate treatment for each patient.

Correspondence: Sociedade Brasileira de Cardiologia – Av. Marechal Câmara, 360/330 – Centro – Rio de Janeiro – CEP: 20020-907. E-mail: diretrizes@cardiol.br

2025 Brazilian Evidence-based Guideline on the Management of Obesity and Prevention of Cardiovascular Disease and Obesity-Associated Complications: A Position Statement by Five Medical Societies

The report below lists declarations of interest as reported to the SBC by the experts during the period of the development of these statement, 2024/2025.

Expert	Type of relationship with industry
Bruno Halpern	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk, Lilly, Boehringer Ingelheim, Astra Zeneca, Merck, Novartis.
Cynthia M. Valerio	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: Diabetes and Obesity; Boehringer Ingelheim: Diabetes; Eli Lilly: Diabetes and Obesity; AstraZeneca: Diabetes; EMS: Diabetes and Obesity. B - Research funding under your direct/personal responsibility (directed to the department or institution) from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Chiesi: metreleptina. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Chiesi: metreleptina.
Fabiana H. Rached	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: semaglutide; Novartis: inclisiran; Daiichi Sankyo: bempedoic acid. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: semaglutide; Novartis: inclisiran; Daiichi Sankyo: bempedoic acid.
Fabio R. Trujillo	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Aché, Amryt Pharma, Astra Zeneca, BracePharma, EMS, Eurofarma, Lilly, Merck, NovoNordisk, Scitech Medical, Takeda.

Guidelines

Fernando Valente	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: Diabetes and Obesity; Boehringer Ingelheim: Diabetes; Eli Lilly: Diabetes and Obesity, Abbott: CGM, AstraZeneca: Diabetes; Servier: Diabetes; EMS: Diabetes and Obesity; GSK: Vaccines. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - AstraZeneca: Diabetes; NovoNordisk: Diabetes.
João Eduardo N. Salles	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Astra Zeneca, Bayer, Boehringer-Ingelheim, Lilly, Merck serono Novo Nordisk.
José Francisco Kerr Saraiva	Financial declaration C - Personal research funding paid by the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Bayer: finerinone; Novo Nordisk: semaglutide; AstraZeneca: Zirconium cyclosilicate, dapagliflozin; Amgen: evolocumab; Boehringer Ingelheimer: empagliflozin; Lilly: tirzepatide, atorvastatin viatris; Daichii Sankyo: bempedoic acid/Edoxaban; Mantecorp: rosuvastatin. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Bayer: finerinone; Novo Nordisk: Semaglutide; AstraZeneca: Zirconium cyclosilicate, dapagliflozin; Amgen: evolocumab; Boehringer Ingelheimer: empagliflozin; Lilly: tirzepatide, atorvastatin viatris; Daichii Sankyo: bempedoic acid/edoxaban.
Luciano F. Drager	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Lilly, Novo Nordisk, ResMed. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk.
Marcello C. Bertoluci	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - AstraZeneca, NovoNordisk, Lilly, Boehringer, Bayer, Servier, Brace Pharma, Roche, AMGEM.

Marcelo H. V. Assad	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - AstraZeneca: Forxiga; BAYER: Firalta; Biolab: Repath; Boehringer Ingelheim: Glyxambi; Daiichy Sankyo: Benicar, Nustendi; EMS: Bramicar; GSK: Shingrix; Libbs: Stanglit; Lilly: Mounjaro; Novo Nordisk: Wegovy; Novartis: Sybrava; Pfizer: Prevenar 20; Viatris: Lipitor, Inspira. B - Research funding under your direct/personal responsibility (directed to the department or institution) from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - AMGEN: Olpasirana. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Bayer: Firalta; Daiichi Sankyo: Benicar; Novo Nordisk: Wegovy.
Marcio C. Mancini	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Merck: Contrave; Novo Nordisk: Wegovy; EMS: Olyra; Myralis: Mecobe. B - Research funding under your direct/personal responsibility (directed to the department or institution) from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Abbott: FreeStyle Libre. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: Wegovy.
Neuton Dornellas	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: a meeting (Advisory board) on the SOUL study - Oral Semaglutide. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: registration, travel and accommodation for the European obesity congress.
Paulo A. C. Miranda	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - NovoNordisk, Lilly, Recordat, Ache, Ipsen.

Guidelines

Rodrigo N. Lamounier	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Abbot: FreeStyle Libre; Minimed: Sistema 780G; EMS: Olira; Lilly: Mounjaro. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: Ozempic, Wegovy.
Rodrigo O. Moreira	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Bayer, Astra Zeneca, Novo Nordisk, Eli Lilly, Libbs, EMS, Eurofarma, Chiesi, Servier. B - Research funding under your direct/personal responsibility (directed to the department or institution) from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Servier, AMRYT Pharma. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Astra Zeneca, Novo Nordisk, Bayer, Servier.
Ruy Lyra da Silva Filho	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Abbott, Biolab, Boheringer, Lilly, Merck Serono, Eurofarma, MSD, Roche, Bayer, Mantecorp. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Abbott, Mantecorp, Boheringer, Lilly, Biolab, Eurofarma, Novo Nordisk, Bayer.
Sergio E. Kaiser	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Bayer: Firlalta; Novo Nordisk: Ozempic e Wegovy; Daiichi Sankyo: Nustendi e Benicar; Astrazeneca: Forxiga, Selozok; Novartis: Sybrava; Libbs: Plenance, Naprix; Biolab: Repatha e Livalo. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novo Nordisk: Wegovy; Libbs: Naprix; Astrazeneca: Selozok.

Simone Van de Sande-Lee	Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the Brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Abbott: Diabetes; Lilly: Obesity and Diabetes; Novo Nordisk: Obesity.
Viviane Z. Rocha Giraldez	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the Brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Abbott: Lipidil; Aché: Trezete; Biolab: Repatha; Daichi-Sankyo: Nustendi; Lilly: Mounjaro; Novartis: Sybrava; Novo-Nordisk: Wegovy; Ultragenyx: Evkeeza. Other relationships Funding of continuing medical education activities, including travel, accommodation and registration in conferences and courses, from the Brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Novartis: Sybrava; Novo Nordisk: Wegovy.
Wellington S. da Silva Junior	Financial declaration A - Economically relevant payments of any kind made to (i) you, (ii) your spouse/partner or any other person living with you, (iii) any legal person in which any of these is either a direct or indirect controlling owner, business partner, shareholder or participant; any payments received for lectures, lessons, training instruction, compensation, fees paid for participation in advisory boards, investigative boards or other committees, etc. from the Brazilian or international pharmaceutical, orthosis, prosthesis, equipment and implants industry: - Abbott, AstraZeneca, Libbs, Lilly, Novartis, Novo Nordisk.

Table of contents

Introduction	8
Methodology	8
Part 1 – Cardiovascular Risk Definition	10
1.1. Assessment of cardiovascular Risk in individuals with overweight or obesity.....	10
1.2. Heart failure screening in individuals with overweight or obesity ...	11
Part 2 – Weight Loss Targets	13
2.1. Weight Loss Targets for Risk Factor Improvement	13
2.2. Weight Loss Targets for Cardiovascular Event Reduction	13
2.3. Weight loss Targets for Atrial Fibrillation-Related Complications.....	14
Part 3 – Obesity Management	14
3.1. Lifestyle Modification.....	14
3.2. Pharmacotherapy management for reducing events and risk factors	15
3.2.1. Obesity and Moderate or High ASCVD risk	15
3.2.2. Obesity and Established ASCVD risk	16
3.2.3. Obesity and type 2 Diabetes.....	16
3.2.4. Obesity, Type 2 Diabetes, and Chronic Kidney Disease	18
3.2.5. Obesity and Obstructive Sleep Apnoea	18
3.2.6. Obesity and Heart Failure.....	21
3.2.7. Obesity in Individuals with High Heart Failure Risk	21
3.3. Bariatric Surgery.....	21
3.3.1. Obesity Stage 2 and Moderate/High ASCVD Risk or High HF Risk.....	22
3.3.2. Obesity Stage 2 and Heart Failure.....	22
Conclusion	23
Supplement	23
References	24

Introduction

Global obesity prevalence has nearly tripled since 1975, now affecting over one billion people. Obesity is widely recognised as a condition associated with numerous chronic diseases, significantly impairing quality of life and reducing life expectancy.¹

In 2021, 612 million individuals were affected by cardiovascular disease (CVD), accounting for 26.8% of all deaths worldwide. This figure has increased by 0.88% over the past 30 years. Notably, 79.5% of all disability-adjusted life years (DALYs) lost can be attributed to 11 risk factors, with body mass index (BMI) showing the strongest association.² Furthermore, prevalence studies have shown that approximately two-thirds of obesity-related deaths are due to CVD.^{2,3} The Brazilian data from 2025 show that 68% of adults have a BMI of at least 25 kg/m², with 31% classified as living with obesity. In 2021 alone, 60,913 premature deaths in Brazil were attributed to elevated BMI.¹

The relationship between obesity and CVD is well-established. Prospective epidemiological studies have shown that obesity increases the risk of coronary artery disease (CAD) events and cardiovascular mortality.⁴ Obesity contributes to the development of CVD through multiple pathways, either indirectly through increased traditional cardiovascular (CV) risk factors, such as type 2 diabetes, dyslipidaemia, and hypertension, or directly

through an adiposity-induced inflammatory state that affects cardiac structure and function.^{5,6}

Multiple epidemiological studies have related obesity to CVD through BMI. A meta-analysis of over 300,000 adults showed that BMI-defined overweight and obesity ranges are associated with increased risk of CAD and CV mortality. Observational and Mendelian randomisation studies have indicated a strong direct link between higher BMI and increased heart failure incidence and mortality.⁷

In addition, abdominal obesity is reported as more directly associated with increased risk of cerebrovascular disease, coronary heart disease, and CV mortality.⁵ Meta-analyses of large cohort studies showed that abdominal obesity, measured by waist circumference, is a strong independent predictor of morbidity and mortality across all BMI categories.^{5,6} Even individuals with a BMI below 30 kg/m² may present with elevated cardiometabolic risk, particularly when visceral fat accumulation is accompanied by a relative deficiency in gluteofemoral subcutaneous fat and other risk factors.⁸ Therefore, alternative measurements to BMI, such as waist circumference, waist-to-hip ratio, and waist-to-height ratio are recommended to better identify individuals with potential visceral adiposity.⁹⁻¹¹

Despite the availability of various treatment options, including lifestyle interventions, pharmacotherapy, and bariatric surgery, the management of obesity remains challenging. Achieving and maintaining weight loss can be challenging, and the long-term outcomes of obesity treatment are frequently modest. Moreover, the increasing complexity of anti-obesity treatments, some with proven benefits in cardiorenal-metabolic syndrome outcomes, underscores the urgent need for new stratification tools to guide treatment selection in specific clinical situations.^{12,13}


Accordingly, this guideline aims to structure obesity treatment within the context of CVD prevention, considering both CV risk and obesity stage. It provides evidence-based recommendations to support healthcare professionals in personalizing optimal therapeutic strategies for individuals living with obesity.

Methodology

The guideline was developed using the Delphi method,¹⁴ a structured process involving successive rounds of expert input, in which participants respond anonymously and are afforded opportunities to revise their responses based on feedback from other participants.

An initial panel of twenty experts from five medical societies, Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO), Brazilian Diabetes Society (SBD), Brazilian Society of Endocrinology and Metabolism (SBEM), Brazilian Cardiology Society (SBC), and Brazilian Sleep Academy (ABS), were recruited. From this panel, five members formed the working group (steering committee) responsible for designing the guideline framework, consisting of 25 evidence-based recommendations.

Each recommendation was designed to address a specific clinical situation and assigned a recommendation grade



Cardiovascular risk assessment strategy in adults with overweight or obesity

(12 ≥ 25%), a single RCT, prespecified subgroup analysis, large observational studies, or meta-analyses of observational studies. C—Data from small or nonrandomized studies, exploratory analyses, clinical practice guidelines, or expert consensus statements. The level of agreement determined the strength of the recommendation, as follows: I—IS RECOMMENDED: >90% agreement among panel members; IIa—SHOULD BE CONSIDERED: 70-90% agreement; IIb—MAY BE CONSIDERED: 50–70% agreement; and III—IS NOT RECOMMENDED: <50% agreement or majority against. Recommendation grades and levels of evidence were established according to the guideline provided in Tables 1 and 2.

Term	Definition	Class of recommendation
RECOMMENDED	≥90% agreement with recommendation among panel members	I
SHOULD BE CONSIDERED	75–89% agreement with recommendation	IIa
MAY BE CONSIDERED	50–74% agreement with recommendation	IIb
NOT RECOMMENDED	<50% agreement with recommendation	III

Guidelines

Table 2 – Level of evidence

Level of Evidence	Definition	Color
A	≥2 randomized clinical trials (RCTs) or meta-analysis of RCTs with low heterogeneity ($I^2 < 25\%$)	
B	Meta-analysis of observational studies, meta-analysis with high heterogeneity ($I^2 \geq 25\%$), a single RCT, large longitudinal observational studies or prespecified subgroup meta-analyses of large RCTs.	
C	Estudos transversais, experimentos, estudos de casos e controles, série de casos, análises exploratórias, diretrizes de sociedades, opinião de experts	

Part 1 – Cardiovascular Risk Definition

1.1.1. Assessment of Cardiovascular Risk in Individuals with Overweight or Obesity

R1.	Class of recommendation	Level of evidence
Assessing and categorising the risk of atherosclerotic cardiovascular disease (ASCVD) and Heart Failure (HF) is RECOMMENDED for all adults with overweight or obesity over the age of 18 years to guide anti-obesity treatment.	I	C

Summary of evidence (R1):

- Considering emerging evidence on the CV benefits of medications in reducing the risk of atherosclerotic CV disease (ASCVD) and HF in individuals with obesity, the selection of anti-obesity treatment should be guided by CV risk stratification. This recommendation is based on expert consensus.

R2.	Class of recommendation	Level of evidence
Using the PREVENT risk score for CV risk assessment is RECOMMENDED for individuals with overweight or obesity with a BMI $< 40 \text{ kg/m}^2$ who are aged 30–79 years in the primary prevention of CVD, using the mode that includes the glycated haemoglobin (HbA1c) value and assessing both total ASCVD risk and 10-year heart failure (HF) risk to guide obesity management.	I	C

Summary of evidence (R2):

- The Predicting risk of CVD Events (PREVENT) equations was preferred over the older Pooled Cohort Equations due to its greater ethnic representativeness, larger population inclusion, and improved accuracy. However, the PREVENT score is limited in CVD subtype coverage. The PREVENT model incorporates expanded outcomes, including HF and risk factors related to obesity, diabetes, and kidney disease. The risk model demonstrates good prognostic performance with appropriate discrimination and calibration in both general populations and demographic/CV-kidney-metabolic subgroups.^{15,16}

- Designed for individuals with overweight or obesity, the PREVENT risk score should be applied using the mode that includes HbA1c measurement. Both total ASCVD risk and 10-year HF risk should be evaluated. The PREVENT score has limitations regarding age and BMI levels and should be restricted to patients aged 30 to 79 years with a BMI $< 40 \text{ kg/m}^2$. Additionally, the PREVENT score was developed for primary prevention patients – it should not be used for risk stratification in patients with established ASCVD and/or HF.

R3.	Class of recommendation	Level of evidence
Categorising CV risk in individuals with overweight or obesity as LOW, MODERATE, or HIGH ASCVD risk and HIGH HF risk is RECOMMENDED to guide obesity management. (Table 3 and Central Illustration).	I	C

The proposed strategy for CV risk assessment in adults with overweight or obesity is shown in **Central Illustration**.

Important Note 1: When to re-stratify individuals with MODERATE ASCVD RISK

- Individuals at moderate risk according to the PREVENT score who require ASCVD risk re-stratification due to family history of premature CAD should undergo coronary artery calcium scoring via thoracic computed tomography scan.

- Those with CAC >100 AU without diabetes or CAC >10 AU with diabetes, should be reclassified as HIGH RISK. Individuals with CAC = 0 and diabetes should remain classified as moderate risk.
- Patients with type 2 diabetes for more than 10 years or those with chronic kidney disease (estimated glomerular filtration rate [eGFR] <45 mL/min/1.73 m² and/or albuminuria with a urine albumin-to-creatinine ratio (ACR) >30 mg/g) or BMI >40 kg/m², even if asymptomatic, should be classified as HIGH RISK, regardless of their PREVENT score.

1.2. Heart Failure Screening in Individuals with Overweight or Obesity

R4.	Class of recommendation	Level of evidence
Screening for HF using natriuretic peptides (N-terminal pro-B-type natriuretic peptide [NT-proBNP] or B-type natriuretic peptide [BNP]) or imaging SHOULD BE CONSIDERED in individuals with HIGH HF RISK (see thresholds in Important Note 2).	Ila	C

Summary of evidence (R4):

- Obesity is an important risk factor for HF with preserved ejection fraction (HFpEF). Individuals with

obesity are often diagnosed late, by which time significant cardiac dysfunction may already be present. This delay is frequently due to the misattribution of symptoms, particularly in advanced stages, to obesity.¹⁷

- For individuals with obesity with HIGH HF risk, screening for type 2 diabetes, hypertension, atrial fibrillation, and obstructive sleep apnoea (OSA) and obtaining objective evidence of exercise intolerance can identify the need for HF-targeted interventions. Timely HF treatment improves prognosis regarding quality of life and morbidity/mortality.¹⁸.

- The association between the apnoea-hypopnea index (AHI) and CV mortality is positive but of moderate magnitude. A meta-analysis found a hazard ratio [HR] of 2.07 (95% confidence interval [CI]: 1.48–2.91) for CV mortality in patients with severe OSA (AHI ≥30 events/hour) versus controls, while another study found a relative risk (RR) of 1.79 (95% CI: 1.47–2.18) for CV events at this severity level.¹⁹ Dose-response analyses show that each 10-event/hour increase in AHI is associated with a 9–17% increase in CV event risk. The strength of this association varies by subgroup: the risk is more prominent in men under 70 years and individuals with excessive daytime sleepiness. The risk is lower or nonsignificant for mild-to-moderate OSA, indicating a dose-response effect with greater impact at higher AHI levels.²⁰ (see Important Note 3).

As shown in Figure 1, the flowchart provides a summary of the management of obesity and its complications, guided by cardiovascular risk assessment.

Table 3 – Cardiovascular Risk Assessment in Individuals with Overweight or Obesity

ASCVD RISK	DEFINITION
LOW <5% at 10 years	• Individuals with overweight or obesity with BMI <40 kg/m² aged <30 years without CV risk factors (see Important Note 1). • Individuals with overweight or obesity aged ≥30 years with total ASCVD risk by PREVENT score <5% at 10 years.
MODERATE 5% to <20% at 10 years	• Individuals with overweight or obesity with BMI <40 kg/m² without prior CV events, with ≥1 risk factor (see Supplement 1). • Individuals with overweight or obesity with BMI <40 kg/m² in primary prevention, with total CV risk by PREVENT score 5% to <20% at 10 years.
HIGH ≥20% at 10 years	• Established coronary artery disease, myocardial infarction (MI), ischaemic stroke or transient ischaemic attack (TIA), peripheral artery disease (PAD), arterial revascularisation in any territory. • Primary prevention with total CV risk by PREVENT score ≥20% at 10 years. • Type 2 diabetes duration >10 years. • Chronic kidney disease stage 3b/4/5 (see Important Note 1). • Coronary artery calcium (CAC) score >100 Agatston Units (AU) (without diabetes) or >10 AU (with diabetes), Lp(a) >50 mg/dL or >125 nmol/L, familial hypercholesterolaemia (FH), or LDL-C >190 mg/dL.

Guidelines

HIGH HF RISK

≥20% at 10 years

- BMI >40 kg/m², even if asymptomatic.
- Individuals with obesity plus diabetes and hypertension.
- Severe obstructive sleep apnoea (OSA)
- Atrial fibrillation.
- Chronic kidney disease stage 3b/4/5 (see Important Note 1).
- Elevated NT-proBNP or BNP.
- PREVENT HF risk score ≥20% at 10 years.
- Established ASCVD.
- Symptoms suggestive of HF.

Note: For convenience, the moderate risk category encompasses both borderline (5–7.5% over 10 years) and intermediate (7.5 to <20% over 10 years) risk levels.

Legends: Agatston Units: AU; ASCVD: atherosclerotic cardiovascular disease; BMI: body mass index; CVD: Cardiovascular disease; HF: Heart failure; CAD: Coronary artery disease; CKD: Chronic kidney disease; CAC: Coronary artery calcium; FH: Familial hypercholesterolaemia; OSA: Obstructive sleep apnea; Lp(a): Lipoprotein(a); LDL-c: Low-density lipoprotein cholesterol; BNP: B-type natriuretic peptide, NT-proBNP: N-terminal pro-B-type natriuretic peptide

Treatment of Obesity and its Complications Based on Cardiovascular Risk



Established HF:

- LSM with >10% weight loss: ↑QoL, ↑Cardiac function, ↑Exercise capacity
- SGLT2i: ↓HF hospitalization and ↓CV death
- Combination SGLT2i+Semaglutide (HFpEF): ↓HF-related outcomes, ↓All-cause mortality
- Semaglutide or tirzepatide (HFpEF): ↑QoL, ↓HF symptoms
- GLP-1 RA (HFpEF - NYHA II,III): ↓weight, ↑QoL
- Bariatric surgery (BMI>35) (cautiously): ↓HF hospitalization and ↑Cardiac function

High HF Risk:

- Semaglutide SC (HFpEF): ↑QoL, ↓onset of HF symptoms
- Tirzepatide (HFpEF): ↑QoL, ↓onset of HF symptoms
- Semaglutide SC (obesity): ↓HF with high ASCVD risk
- Combination: SGLT2i + semaglutide or tirzepatide: ↓MACE
- Bariatric surgery [Obesity BMI>35 kg/m²]: ↓HF risk

Established ASCVD: Secondary Prevention

- Semaglutide SC 2.4 mg (Obesity): ↓MACE and ↓All-cause mortality
- Oral Semaglutide (T2D): ↓MACE
- SGLT2i (T2D): ↓MACE
- Combination SGLT2i+Semaglutide (T2D): ↓MACE
- Bariatric Surgery (Obesity BMI>35): ↓MACE

High Risk with Diabetes (Primary Prevention)

- Liraglutide 1.8: ↓MACE
- Dulaglutide 1.5: ↓MACE
- Semaglutide SC 1.0 and oral semaglutide: ↓MACE
- Semaglutide SC 1.0 mg (CKD and T2D): ↓MACE, ↓Kidney outcomes
- SGLT2i (Subclinical CAD): ↓MACE
- LSM with >10% weight loss (Obesity+T2D): ↓MACE

Moderate ASCVD Risk:

- GLP-1 RA (Obesity): ↓risk factors
- Tirzepatide (Obesity): ↓risk factors, ↓OSA
- LSM with >5% weight loss (Obesity): ↓CV risk factors

● IS RECOMMENDED ● MUST BE CONSIDERED ● CAN BE CONSIDERED

Legend: ASCVD: atherosclerotic cardiovascular disease; BMI: body mass index; CAD: coronary artery disease; CKD: chronic kidney disease; CVD: cardiovascular disease; DLP: dyslipidemia; GLP-1 RA: GLP-1 receptor agonist; GLP-1/GIP RA: dual GLP-1/GIP receptor agonist; HF: heart failure; HF-related outcomes: outcomes related to heart failure; HFpEF: heart failure with preserved ejection fraction; HFrEF: heart failure with reduced ejection fraction; HTN: hypertension; IS: ischemic stroke; LSM: lifestyle modification; MACE: major adverse cardiovascular events (CV death, non-fatal MI, and non-fatal stroke); NYHA: New York Heart Association; OSA: obstructive sleep apnea; QoL: quality of life; Revascularization: arterial revascularization surgery; T2D: type 2 diabetes

Figure 1 – Treatment of Obesity and its Complications Based on Cardiovascular Risk

Important Note 2: Additional testing for HF

- Individuals with elevated NT-proBNP or BNP or with HF symptoms should undergo further diagnostic evaluation.
- NT-proBNP and BNP levels must be interpreted in the context of obesity, as lower levels are observed in individuals with obesity compared with individuals without obesity.⁸
- The NT-proBNP exclusion threshold for HF (<125 pg/mL) has low sensitivity (67%) in individuals with a BMI >35 kg/m². In these individuals, a lower exclusion threshold (50 pg/L) showed higher sensitivity (93–98%). Conversely, the inclusion threshold >220 pg/ml achieved higher specificity (82–89%).²¹
- Using NT-proBNP or BNP alone to guide HF diagnosis in individuals with obesity requires careful consideration. When the clinical signs and symptoms of HF are present, even with normal values, additional diagnostic testing is recommended.^{17,21}
- In conditions such as atrial fibrillation, further investigation with echocardiography, electrocardiography, or 24-hour Holter monitoring may be necessary.

Important Note 3: Classification of obstructive sleep apnoea

The AHI is the most widely used measure for classifying OSA severity. It is calculated by summing Aneas and hypopneas (respiratory flow reductions) and dividing by the total sleep hours (or hours of monitoring).

- Normal: AHI <5 events/h.
- Mild: AHI 5.0–14.9 events/h.
- Moderate: AHI 15.0–29.9 events/h.
- Severe: AHI ≥30 events/h.

Part 2 – Weight Loss Targets

2.1. Weight Loss Targets for Risk Factor Improvement

R5.	Class of recommendation	Level of evidence
Sustained weight reduction of at least 5% is RECOMMENDED in individuals with overweight or obesity at MODERATE ASCVD RISK to reduce CV risk factors, such as hypertension and dyslipidaemia, and delay or prevent type 2 diabetes onset.	I	A

Summary of evidence (R5):

- Lifestyle modification (LSM) studies including the Diabetes Prevention Programme (DPP) and Look AHEAD study have demonstrated that modest weight loss of at least 5% of body weight significantly reduces cardiometabolic risk factors.^{22,23}
- The DPP randomised 3,234 individuals with prediabetes or glucose intolerance to receive placebo, metformin (850 mg twice daily), or a lifestyle intervention targeting ≥7% weight loss and at least 150 minutes of physical activity per week. After 2.8 years of follow-up, lifestyle intervention reduced the incidence of diabetes by 58% (95% CI: 48–66%), while metformin reduced it by 31% (95% CI: 17–43%) compared with that observed with the placebo.²²
- The Look AHEAD study was a RCT that evaluated intensive lifestyle intervention versus diabetes support and education in 5,145 adults with overweight or obesity (mean BMI = 36 kg/m²) and type 2 diabetes. The primary endpoint was a composite of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalisation for angina. The trial was terminated early due to futility after a median follow-up of 9.6 years. Although the primary endpoint was not met, intensive lifestyle intervention achieved higher weight loss (8.6% vs. 0.7% at 1 year; 6.0% vs. 3.5% at study end) and produced higher reductions in HbA1c and CV risk factors [23]. The magnitude of weight loss at 1 year was strongly associated with improvements in glycaemia, blood pressure, triglyceride levels, and high-density lipoprotein (HDL) cholesterol ($p < 0.0001$) but not with low-density lipoprotein (LDL) cholesterol ($p = 0.79$). Compared with stable-weight participants,

individuals who lost 5 to <10% (7.25 ± 2.1 kg) of body weight had greater odds of achieving HbA1c reduction (odds ratio [OR] 3.52 [95% CI: 2.81–4.40]), 5 mmHg reduction in diastolic blood pressure (OR 1.48 [1.20–1.82]), 5 mmHg reduction in systolic blood pressure (OR 1.56 [1.27–1.91]), 40 mg/dL reduction in triglyceride levels (OR 2.20 [1.71–2.83]), and 5 mg/dL increase in HDL cholesterol (OR 1.69 [1.37–2.07]).²⁴

2.2. Weight Loss Targets for Cardiovascular Event Reduction

R6.	Class of recommendation	Level of evidence
Sustained reduction of at least 10% from maximum weight SHOULD BE CONSIDERED in adults with overweight or obesity at MODERATE or HIGH ASCVD RISK to reduce CV events.	IIa	B

Summary of evidence (R6):

- The Da-Qing study was a Chinese RCT evaluating the effect of 6-year lifestyle intervention outcomes in 577 individuals with prediabetes and overweight (mean BMI = 25.7 kg/m²) on diabetes incidence, CV events, microvascular complications, CV death, all-cause mortality, and life expectancy. After 30 years of follow-up, reductions in CV events (HR 0.74, 95% CI: [0.59–0.92]), CV death (HR 0.67, 95% CI: [0.48–0.94], $p = 0.022$), and all-cause mortality (HR 0.74, 95% CI: [0.61–0.89], $p = 0.0015$) were observed, and diabetes diagnosis was delayed by up to 4 years.²⁵
- Although the primary endpoint in the Look-AHEAD study was not met, *post hoc* observational analysis suggests an association between initial weight loss magnitude and long-term CV event reduction in individuals with obesity and type 2 diabetes. Over a mean follow-up of 10.2 years (interquartile range [IQR] 9.5–10.7), individuals who lost ≥10% of body weight in the first year had 21% lower risk of the primary outcome (adjusted HR: 0.79, 95% CI: 0.64–0.98; $p = 0.034$) and 24% lower risk of the secondary outcome (adjusted HR 0.76, 95% CI: 0.63–0.91; $p = 0.003$) compared with that observed with those who had stable weight or weight gain. In the analyses using the control group as reference, participants who received intensive lifestyle intervention and lost ≥10% of body weight had 20% lower risk of the primary outcome (adjusted HR: 0.80, 95% CI:

Guidelines

0.65–0.99; $p = 0.039$) and 21% lower risk of the secondary outcome (adjusted HR 0.79, 95% CI: 0.66–0.95; $p = 0.011$).^{26,27}

- The Semaglutide Effects on Cardiovascular Outcomes in Individuals with Overweight or Obesity (SELECT) trial demonstrated the superiority of semaglutide 2.4 mg subcutaneous (SC) over placebo in reducing CV events in individuals with obesity and established CVD. Notably, the observed CV benefit was associated with a modest weight reduction of 9%.

- Subsequent analyses indicated that achieving much benefit is weight-loss independent, particularly for major adverse CV event (MACE) reductions observed early in the trial before significant weight loss was achieved. However, the contribution of weight loss to these benefits cannot be ruled out.²⁸

- Bariatric surgery has also shown reduction in CV events and mortality in populations with obesity. The Swedish Obese Subjects (SOS) study, a prospective, non-randomised cohort study, evaluated 4,047 individuals with obesity (BMI ≥ 34 kg/m² for men and ≥ 38 kg/m² for women), of whom 2,010 underwent bariatric surgery (gastric banding, vertical banded gastroplasty, or gastric bypass) and 2,037 received conventional obesity treatment. The mean follow-up duration was 14.7 years. Mean weight loss in the surgical group at 10 years was 17% (vs. 1% in the conventional treatment group). For composite CV events (fatal and nonfatal myocardial infarction, fatal and nonfatal stroke, angina pectoris, and HF), the surgical group showed a significant 33% reduction, plus 53% reduction in CVD death (HR 0.47; 95% CI: 0.29–0.76; $p = 0.002$) compared with that observed with conventional treatment. Although surgery-specific effects cannot be excluded, the fact that >80% of the procedures were restrictive (vertical banded gastroplasty and gastric banding, where hormonal effects contributing to weight loss are less relevant) indicates that the main factor associated with MACE reduction was significant (>15%), and it sustained weight loss.²⁹

- Based on the available evidence, the panel recommends a weight loss target of at least 10% from maximum lifetime weight³⁰ for individuals at moderate or high ASCVD risk, as a strategy to reduce CV events.

2.3. Weight Loss Targets for Atrial Fibrillation-Related Complications

R7.	Class of recommendation	Level of evidence
Sustained weight reduction of at least 10% is RECOMMENDED in individuals with obesity and paroxysmal or permanent atrial fibrillation (AF) to reduce the risk of AF-related complications.	I	B

Summary of evidence (R7):

- Weight reduction in individuals with obesity has demonstrated a positive impact on reducing symptom burden and AF recurrence.³¹
- A single-centre, partially blinded RCT conducted in Australia that enrolled 150 individuals with obesity or overweight and

AF showed that a structured weight management programme significantly reduced symptom burden, severity, and number of AF episodes over 15 months of follow-up. The intervention group compared with the control group lost more weight (14.3 kg vs. 3.6 kg) and had higher reductions in symptom severity scores and interventricular septal thickness.³²

- Another meta-analysis revealed that weight loss of at least 10% is associated with lower AF recurrence, reduced AF burden, and improved symptom severity.³³ Similarly, weight loss following catheter ablation reduced AF recurrence at 12 months of follow-up.³⁴

- In the SOS study, bariatric surgery reduced the risk of new-onset AF compared with that observed with usual care. Risk reduction was more pronounced in younger individuals and those with elevated diastolic blood pressure.³⁵

Part 3. Obesity Management

3.1. Lifestyle Modification

R8.	Class of recommendation	Level of evidence
Adoption of lifestyle modification measures (LSM) is RECOMMENDED for all individuals with overweight or obesity, regardless of CV risk, to reduce weight, improve health and quality of life, and prevent hypertension, type 2 diabetes, dyslipidaemia, ASCVD, and HF.	I	A

Summary of evidence (R8):

- Lifestyle modification measures (LSM) in individuals with overweight or obesity should include a dietary programme with appropriate and healthy macronutrient distribution combined with aerobic and resistance exercises.³⁶

- The LSM approach should be multidisciplinary, with a team including a dietitian, exercise physiologist and psychologist, delivered through individual or group sessions. Incorporation of LSM should not delay the initiation of anti-obesity pharmacotherapy, when indicated.³⁷

- Nutritional counselling should focus on reducing portion sizes, increasing intake of fruits and vegetables, and reducing consumption of alcohol and ultra-processed foods. Moreover, it should target an initial energy deficit of 500–750 kcal/day, which will need further adjustments based on body weight and individual activity levels.³⁷

- RCTs evaluating medications with moderate weight loss effects, including sibutramine,³⁸ liraglutide,³⁹ and bupropion/naltrexone combination,⁴⁰ demonstrated that combination with LSM produced superior results for body weight reduction and cardiometabolic risk factors.

- The advent of more potent anti-obesity medications, such as semaglutide⁴¹ and tirzepatide,⁴² has led to the possibility of greater

caloric deficits and, as a result, enhanced weight reduction. In this context, it is essential to closely monitor the consumption of various macronutrients, particularly protein, to avoid sarcopenia and nutritional deficiencies. This approach will ensure the establishment of healthy and sustainable eating habits.⁴³

- Similarly, a healthy diet can be achieved with dietary patterns rich in fresh and minimally processed foods, such as Mediterranean and Dietary Approaches to Stop Hypertension diets, which include whole grains, fruits and vegetables, lean white meats, and plant protein sources such as legumes and nuts.^{44,45} These dietary patterns reduce cardiometabolic risk⁴⁵ and may serve as references but should be adapted for Brazilian preferences and contexts to support adherence.⁴⁶ Limiting the intake of ultra-processed foods rich in saturated fats and refined sugars is also recommended, as these have been linked to poorer body composition and elevated all-cause and cardiovascular mortality rates.⁴⁷

3.2. Pharmacotherapy Management for Reducing Events And risk Factors

3.2.1. Obesity and Moderate or High ASCVD Risk

R9.	Class of recommendation	Level of evidence
Treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 RA) or GLP-1/Glucose-dependent insulintropic polypeptide (GIP) receptor co-agonist is RECOMMENDED for adults with overweight or obesity at MODERATE or HIGH ASCVD RISK to reduce weight and CV risk factors.	I	A

Summary of evidence (R9):

- Liraglutide, a GLP-1 RA with weight loss efficacy at 3.0 mg/day, had its effects on obesity and complications evaluated in the Satiety and Clinical Adiposity–Liraglutide Evidence (SCALE) programme. The SCALE Obesity and Prediabetes trial randomised 2,254 patients to receive liraglutide 3.0 mg or placebo. After 56 weeks, 63.2% and 33.1% of the patients lost >5% and >10% of initial weight, respectively. After 3 years, the risk of developing diabetes was reduced by 79% in patients with prediabetes; patients on liraglutide compared with those on placebo took 2.7 times longer to develop diabetes.⁴⁸

- A *post hoc* analysis using pooled data from 5,908 individuals across 5 RCTs in the SCALE programme (liraglutide vs. placebo or orlistat) demonstrated the CV safety of liraglutide 3.0 mg in individuals with obesity.⁴⁹

- The Semaglutide Treatment Effect in Individuals with Obesity (STEP 1) trial included 1,961 patients with overweight or obesity without type 2 diabetes who were followed up for 68 weeks. All individuals received a reduced-calorie diet with 500 kcal/day deficit

and counselling for 150 minutes of weekly physical activity. At the end of the study, participants in the semaglutide 2.4 mg group lost 16.9% of body weight, with nadir around week 60, while the placebo group lost 2.4%.⁵⁰

- Tirzepatide, a GLP-1/GIP receptor co-agonist, also demonstrated efficacy in reducing progression to diabetes in patients with obesity and prediabetes. In an analysis of SURMOUNT-1 including 1,032 individuals with obesity and prediabetes treated with tirzepatide for approximately 3 years (176 weeks), type 2 diabetes incidence was lower than that observed with the placebo (1.3% vs. 13.3%; HR 0.07 [95% CI: 0.0–0.1; $p < 0.001$). Additionally, after 17 weeks of tirzepatide discontinuation, 2.4% of the tirzepatide group vs. 13.7% of the placebo group developed type 2 diabetes (HR 0.12, 95% CI: 0.1–0.2; $p < 0.001$). In absolute terms, 99% of individuals with prediabetes who received tirzepatide remained diabetes-free. Mean weight loss in the tirzepatide 5 mg, 10 mg, and 15 mg groups was -12.3%, -18.7%, and -19.7%, respectively, versus -1.3% in the placebo group at 3 years ($p < 0.001$ versus placebo for all comparisons). Furthermore, weight loss exceeding 20% was associated with an HR for type 2 diabetes progression of 0.07, with a number need to treat (NNT) of 9 to prevent one case, and with 92% of patients achieving normoglycaemia, reinforcing the importance of weight loss in diabetes prevention.⁵¹

- Regarding individuals with obesity and diabetes, a systematic review evaluated the effect of non-insulin antidiabetic medications on weight loss in individuals with type 2 diabetes across multiple RCTs. Liraglutide, semaglutide, and tirzepatide resulted in greater weight loss compared with that observed with other therapeutic classes (weight loss > 5%).⁵²

R10.	Class of recommendation	Level of evidence
Use of other anti-obesity medications with proven CV safety MAY BE CONSIDERED in adults with overweight or obesity at MODERATE or HIGH ASCVD RISK when GLP-1 RA or GLP-1/GIP receptor co-agonist are unavailable for treatment (see Table 4).	IIb	B

Summary of evidence (R10):

- Orlistat is a gastric and pancreatic lipase inhibitor that promotes weight reduction by reducing the absorption of 30% of ingested fat. The 'Xenical in the prevention of diabetes in obese subjects' study randomised 3,305 individuals with obesity (BMI ≥ 30 kg/m²) and normal glycaemia (79%) or impaired glucose tolerance (21%) to orlistat (120 mg TID) or placebo, both with LSM. After 4 years of treatment, cumulative diabetes incidence was 9% in the placebo group vs. 6.2% in the orlistat group, corresponding to a risk reduction of 37.3% ($p = 0.0032$). Exploratory analysis demonstrated that greater weight loss

Guidelines

was the primary determinant of diabetes prevention. Over 4 years, individuals using orlistat lost more weight than that observed using placebo (5.8 versus 3.0 kg, respectively; $p < 0.001$).⁵³

- In a meta-analysis of four RCTs evaluating naltrexone/bupropion combination versus placebo at 1 year, the weight loss difference was 5.0 kg (95% CI: 3.96–5.94). Compared with placebo, 55% (48–61%) of patients taking the medication achieved $\geq 5\%$ weight loss, and 30% (24–37%) achieved $\geq 10\%$ weight loss.⁵⁴ In the Contrave Obesity Research-Diabetes study evaluating patients with type 2 diabetes, treated patients had a mean reduction of 11.2% in triglycerides (versus -0.8% with placebo) and an increase of 3.0 ± 0.5 mg/dL in HDL cholesterol (versus -0.3 ± 0.6 mg/dL with placebo), with no significant effect on LDL cholesterol.⁵⁵

- CV safety of naltrexone/bupropion was evaluated in the LIGHT trial ($n = 4,454$), which was terminated early following the public disclosure of confidential interim data. However, 50% of the pre-specified events had occurred. MACEs were reported in 102 patients (2.3%) in the placebo group and 90 patients (2.0%) in the naltrexone/bupropion group (HR 0.88; 99.7% CI 0.57–1.34). These findings support the CV safety of naltrexone/bupropion over a mean follow-up period of 2 years, during which weight loss was maintained.⁵⁶ A subsequent systematic review and meta-analysis further confirmed the CV safety profile of the therapy.⁵⁷

- Medications approved in Brazil for obesity treatment that have presented superior weight loss and CV safety when compared to placebo are listed in Table 4. The most common adverse events and contraindications observed are listed in Table 5.⁵⁸

3.2.2. Obesity and Established ASCVD Risk

R11.	Class of recommendation	Level of evidence
Treatment with semaglutide 2.4 mg is RECOMMENDED in individuals with a BMI ≥ 27 kg/m ² without diabetes and with established CVD (secondary prevention) to reduce CV death, myocardial infarction, and stroke (Figure 1).	I	B

Summary of evidence (R11):

- The SELECT trial was an RCT including 17,604 individuals, with overweight or obesity with a mean age of 61.6 years and BMI of 33.34 kg/m², designed to evaluate the secondary prevention of CV events. The study population had no prior diabetes diagnosis, with established CV disease as an inclusion criterion. Mean

weight loss of 9% was achieved. The results demonstrated a 20% reduction in MACE (CV death, nonfatal myocardial infarction, and nonfatal stroke) (6.5% versus 8.0% with placebo, HR 0.80, 95% CI: 0.72–0.90, $p < 0.001$).⁵⁹

R12.	Class of recommendation	Level of evidence
Use of sibutramine is NOT RECOMMENDED in individuals with obesity and high ASCVD risk.	III	B

Summary of evidence (R12):

- The ‘Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects’ (SCOUT) study evaluated sibutramine versus placebo in individuals with overweight/obesity, prior CVD and/or type 2 diabetes plus one CV risk factor. The risk of a primary endpoint event (nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or CV death) was 11.4% in the sibutramine group compared with 10.0% in the placebo group (HR 1.16; 95% CI: 1.03–1.31; $p = 0.02$). Therefore, this panel considers sibutramine use not recommended in individuals with obesity and high ASCVD risk or chronic CAD.⁶⁰

3.2.3. Obesity and Type 2 Diabetes

R13.	Class of recommendation	Level of evidence
Pharmacological treatment with a GLP-1 RA (liraglutide, dulaglutide, or semaglutide SC or oral) is RECOMMENDED in individuals with type 2 diabetes, obesity or overweight and HIGH ASCVD risk to reduce CV events.	I	A

Summary of evidence (R13):

- Six CV outcome RCTs—LEADER, SUSTAIN-6, REWIND, HARMONY, AMPLITUDE-O, and SOUL—consistently demonstrated the efficacy and safety of GLP-1 RAs in individuals with type 2 diabetes, additionally showing secondary protective effects in individuals with type 2 diabetes and CVD.⁶¹

- A systematic review with meta-analysis of RCTs in patients with type 2 diabetes demonstrated that GLP-1 RAs significantly reduce composite MACE (CV death, nonfatal myocardial infarction, and nonfatal stroke) by 14% and all-cause mortality by 12%. GLP-1 RAs also reduced HF

Table 4 – Summary of the main effects of approved anti-obesity medications in Brazil

	SIBUTRAMINE	ORLISTATE	LIRAGLUTIDE	SEMAGLUTIDE	TIRZEPATIDE	NALTREXONE/ BUPROPION
Prediabetes						
Type 2 Diabetes Glycemic Control						
Lipid Profile						
Blood Pressure						
Obstructive Sleep Apnea						
Polycystic Ovary Syndrome						
Male Hypogonadism						
Metabolic Dysfunction-Associated Steatotic Liver Disease						
Osteoarthritis						
Chronic Kidney Disease						
Cardiovascular Disease					Ongoing	
Heart Failure						
Quality of Life						

ROBUST
RANDOMIZED
CLINICAL TRIALS OR
META-ANALYSES

MINOR/OBS.: MINOR
CLINICAL TRIALS
AND OBSERVATIONAL
STUDIES

CAUTION: CLINICAL
TRIALS WITH
ADVERSE EVENTS
THAT WARRANT
ATTENTION

CV RISK:
CLINICAL TRIALS
WITH CV RISK FOR
HIGH-RISK PATIENTS

NO EVIDENCE

*Studies primarily designed for diabetes treatment were excluded
Adapted from Moreira et al.⁵⁸

Table 5 – Most common and specific side effects of the anti-obesity pharmacologic agents

Medication	More than 10% of patients	Specific side effects that deserve attention
Sibutramine 10-15 mg	Constipation, xerostomia, insomnia	Tachycardia/increased heart rate, increased blood pressure, headache, anxiety
Orlistat 120 mg 3 x/day	Diarrhea/steatorrhea/urgency, flatulence, upper respiratory tract infections/flu, headache, hypoglycemia	Hypersensitivity reactions, long-term deficiency of fat-soluble vitamins
Liraglutide 3.0 mg/day	Nausea and vomiting, diarrhea, constipation	Injection site reactions, increased heart rate, insomnia, cholelithiasis, asthenia and fatigue, hypoglycemia
Semaglutide 2.4 mg/week	Nausea and vomiting, diarrhea, constipation, abdominal pain, headache, fatigue	Injection site reactions, increased heart rate, cholelithiasis, hypoglycemia
Tirzepatide 10 and 15 mg/week	Hypoglycemia (when used with sulfonylureas or insulin), nausea, diarrhea	Hypersensitivity reactions, increased heart rate, injection site reactions
Naltrexone/Bupropion 360/32 mg/day	Nausea, constipation, headache, vomiting	Suicidal thoughts or actions, seizures, risk of opioid overdose, sudden opioid withdrawal, severe allergic reactions, increased blood pressure or heart rate, hepatitis, manic episodes, narrow-angle glaucoma, hypoglycemia (when used with sulfonylureas or insulin), serotonin syndrome

Adapted from Moreira et al.⁵⁸

Guidelines

hospitalisations by 11% and composite kidney outcomes by 21%. Notably, these clinical benefits occur without increased risk of severe hypoglycaemia, retinopathy, or pancreatic adverse events, reinforcing the safety profile of these agents in managing obesity and type 2 diabetes.⁶²

- A systematic review with network meta-analysis demonstrated that GLP-1 RAs significantly reduced all-cause and CV mortality, as well as incidence of nonfatal myocardial infarction, nonfatal stroke, kidney failure, and HF hospitalisations in individuals with type 2 diabetes.⁶³

- The SOUL trial is a double-blind, placebo-controlled RCT that evaluated the CV efficacy of oral semaglutide in 9,650 patients with type 2 diabetes and ASCVD, chronic kidney disease (CKD), or both. After a mean follow-up of 47.5 months, oral semaglutide significantly reduced MACE risk, including CV death, nonfatal myocardial infarction, and nonfatal stroke. Event incidence was 3.1 per 100 person-years in the semaglutide group versus 3.7 per 100 person-years in the placebo group, yielding a 14% relative risk reduction (HR 0.86; 95% CI: 0.77–0.96; $p = 0.006$).⁶⁴

3.2.4. Obesity, Type 2 Diabetes, and Chronic Kidney Disease

R14.	Class of recommendation	Level of evidence
Use of semaglutide 1.0 mg SC once a week SHOULD BE CONSIDERED in patients with obesity or overweight, type 2 diabetes, and CKD with $eGFR \geq 25$ mL/min/1.73 m ² to reduce cardiorenal events.	Ila	B

Summary of evidence (R14):

- The ‘Effect of semaglutide versus placebo on the progression of renal impairment in individuals with type 2 diabetes and chronic kidney disease’ (FLOW) trial was a multicentre study that included 3,534 participants with type 2 diabetes, CKD, and overweight or obesity to investigate the effect of weekly SC semaglutide on kidney disease progression. The composite primary endpoint was persistent $eGFR$ decline of $\geq 50\%$ from baseline, end-stage kidney disease, death from kidney disease, or CV death. The trial was stopped early for efficacy. The trial achieved a significant 24% reduction in kidney disease progression and CV and kidney mortality for individuals treated with semaglutide 1.0 mg. Additionally, semaglutide 1.0 mg had positive impacts on other clinical outcomes: 21% reduction in CV death risk (HR 0.71; 95% CI: 0.56–0.89), 21% reduction in composite renal outcomes (HR 0.79; 95% CI: 0.66–0.94), 18% reduction in the risk of severe CV events (HR 0.82; 95% CI: 0.68–0.98; $p = 0.029$), and a 20% reduction in all-cause mortality (HR 0.80; 95% CI: 0.67–0.95; $p = 0.01$).⁶⁵

Important Note 4 Use of Semaglutide in chronic kidney disease

Semaglutide use can be considered when:

- $eGFR \geq 50$ –75 mL/min/1.73 m² and ACR > 300 to <5,000 mg/g.
- $eGFR = 25$ –50 mL/min/1.73 m² and ACT >100 and <5,000 mg/g.
- $eGFR = 15$ –25 mL/min/1.73 m² (use with caution as evidence is lacking).
- Should be avoided when $eGFR < 15$ mL/min/1.73 m².

3.2.5. Obesity and Obstructive Sleep Apnoea

R15.	Class of recommendation	Level of evidence
Weight loss IS RECOMMENDED for individuals with obesity and obstructive sleep apnoea to improve its severity and/or achieve remission.	I	C

Summary of evidence (R15):

- Evidence regarding the impact of obesity treatment on obstructive sleep apnoea severity and remission has gained increasing attention but still presents significant limitations.⁶⁶
- Regarding non-pharmacological measures, small, randomised studies with short follow-up durations have indicated that interdisciplinary weight reduction strategies can reduce obstructive sleep apnoea severity, particularly in milder cases.^{67,68}
- Remission (normalisation of the apnoea-hypopnea index without need for specific treatments, such as continuous positive airway pressure (CPAP)), may occur in some cases. Importantly, to achieve these results, some studies have adopted highly restrictive intervention measures that are difficult to implement broadly in the long-term.⁶⁹

R16.	Class of recommendation	Level of evidence
Use of liraglutide combined with lifestyle modification MAY BE CONSIDERED in individuals with obesity and moderate-to-severe obstructive sleep apnoea to reduce its severity.	IIb	B

Summary of evidence (R16):

- Regarding pharmacological obesity treatment, randomised trial evidence is currently limited to two studies that have tested two medications (liraglutide and tirzepatide).^{70,71}

- The SCALE study tested liraglutide 3.0 mg daily for 32 weeks in individuals with obesity without diabetes who had moderate or severe OSA and were not using or had not tolerated CPAP adjunctive to diet and exercise. After 32 weeks, mean AHI reduction was greater with liraglutide than with placebo (-12.2 vs. -6.1 events/h), paralleling greater mean weight loss with liraglutide versus placebo (-5.7% vs. -1.6%). This study showed that residual AHI remained significant, suggesting that patients did not achieve OSA remission.⁷⁰

R17.	Class of recommendation	Level of evidence
Use of tirzepatide combined with LSM SHOULD BE CONSIDERED in individuals with obesity and moderate-to-severe OSA to reduce its severity and/or achieve remission.	Ila	B

Summary of evidence (R17):

- The SURMOUNT-OSA trial was a multicentre RCT including 469 patients with obesity and moderate-to-severe OSA, with or without prior CPAP use, randomised to the tirzepatide or placebo group. Compared with the placebo, tirzepatide treatment at 10–15 mg weekly for 52 weeks resulted in 16–17% weight reduction in both sub studies (with or without prior CPAP use). Weight loss was accompanied by AHI reductions of 20 and 24 events per hour compared with that observed with the placebo, and relative event reductions of 48% and 56% in patients with and without CPAP, respectively. A significant proportion achieved OSA remission or ‘non-clinically relevant’ apnoea (mild or asymptomatic).⁷¹

Important Note 5: Tirzepatide in OSA

The SURMOUNT-OSA clinical trial led the Food and Drug Administration to approve tirzepatide as the first medication for treating moderate-to-severe OSA in individuals with obesity, to be used with a reduced-calorie diet and increased physical activity.⁷² The benefits of tirzepatide in reducing OSA severity, body weight, and cardiometabolic markers were observed in individuals, regardless of CPAP use. Randomised studies and meta-analyses have shown that OSA treatment with CPAP alone does not promote weight reduction. Therefore, additional weight reduction measures should be implemented.⁷³

3.2.6. Obesity and Heart Failure

R18.	Class of recommendation	Level of evidence
Weight reduction is RECOMMENDED in individuals with obesity and established HF to improve quality of life, cardiac function, and exercise capacity.	I	A

Summary of evidence (R18):

- A meta-analysis of 19 RCTs and observational studies involving 449,882 individuals with obesity showed that weight loss, although it does not reduce mortality, improves quality of life, ventricular function, and exercise capacity.⁷⁴
- A meta-analysis of 29 studies showed that intentional weight loss through interventions, such as bariatric surgery, can improve cardiac function and quality of life in patients with HF and obesity. Bariatric surgery was associated with reduced risk of developing HF and improvements in diastolic function and left ventricular mass. A J-curve was observed between BMI and HF risk, with maximum risk in severe obesity (BMI >40 kg/m²) of 1.73 (95% CI: 1.30–2.31), $p < 0.001$). Although the obesity paradox was observed for all-cause mortality, the overweight group was associated with lower CV mortality (OR 0.86, 95% CI: 0.79–0.94), with no significant difference among other BMI categories. Bariatric surgery-induced weight loss in individuals with obesity without established HF, atrial fibrillation, or known CAD was associated with reduced left ventricular mass ($p < 0.0001$), improved left ventricular diastolic function ($p \leq 0.0001$), and reduced left atrial size ($p = 0.02$).⁷⁵

R19.	Class of recommendation	Level of evidence
Use of semaglutide (2.4 mg weekly) or tirzepatide (5–15 mg weekly) is RECOMMENDED in individuals with obesity (BMI ≥ 30 kg/m ²) and established HFpEF to reduce weight and improve quality of life and HF-related symptoms.	I	A

Summary of evidence (R19):

- In individuals with established HFpEF, three clinical trials have demonstrated efficacy in improving HF-related outcomes.
- Two RCTs evaluated semaglutide 2.4 mg once weekly in individuals with HFpEF and obesity, demonstrating that the GLP-1 agonist improved HF-related symptoms, functional capacity, and body weight.^{76,77}

Guidelines

- The STEP-HFpEF trial was an RCT comparing semaglutide SC 2.4 mg versus placebo in 529 individuals with obesity, NYHA class II–IV HF, elevated natriuretic peptide levels (with BMI-stratified thresholds at the start of the study), left ventricular ejection fraction >45%, and evidence of echocardiographic abnormalities. Most participants (84%) had left ventricular ejection fraction ≥50%. Treatment with semaglutide 2.4 mg once weekly for 1 year resulted in a significant reduction in body weight (13.3% vs. 2.6% with placebo) and improvements in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) and 6-minute walk distance. Additionally, the reduction in NT-proBNP levels was approximately 15% greater with semaglutide than with the placebo.⁷⁶

- The STEP-HFpEF DM trial compared semaglutide 2.4 mg SC with placebo in individuals with obesity and type 2 diabetes. The results paralleled that of the STEP-HFpEF: semaglutide led to greater reductions in HF-related symptoms and physical limitations and higher weight loss after 1 year of treatment.⁷⁷

- The SUMMIT trial was a 104-week RCT evaluating tirzepatide (titrated to 15 mg SC weekly; n = 364) versus placebo (n = 367) in patients with NYHA class II–IV HF, ejection fraction ≥50%, and BMI ≥30 kg/m². Worsening HF events occurred in 29 patients in the tirzepatide group (8.0%) and 52 patients in the placebo group (14.2%) (HR 0.54; 95% CI: 0.34–0.85). CV death occurred in 8 patients (2.2%) and 5 patients (1.4%), respectively (HR 1.58; 95% CI: 0.52–4.83). Treatment with tirzepatide, compared with placebo, reduced the composite endpoint of CV or HF worsening and improved multiple health status measures in this population, including the KCCQ-CSS, 6-minute walk distance, health status index, and Patient Global Impression of Severity Overall Health Score.⁷⁸

R20.	Class of recommendation	Level of evidence
Use of SGLT2 inhibitors (SGLT2i) is RECOMMENDED in patients with overweight/obesity and established HF (regardless of left ventricular ejection fraction) to reduce hospitalisation and CV death.	I	A

Summary of evidence (R20):

- A pre-specified meta-analysis of the DELIVER and EMPEROR-Preserved trials (n = 12,251) demonstrated that SGLT2i significantly reduced the risk of CV death or HF hospitalisation in individuals with preserved or mildly reduced ejection fraction (HR 0.80; 95% CI: 0.73–0.87).⁷⁹ In the DAPA-HF, EMPEROR-Reduced (reduced ejection fraction), and SOLOIST-WHF (varied ejection fraction) trials, the analysis of 21,947 individuals confirmed reductions in CV death or HF hospitalisation (HR 0.77 [95% CI: 0.72–0.82]); CV death (HR 0.87 [95% CI: 0.79–0.95]); first HF hospitalisation (HR 0.72 [95% CI: 0.67–0.78]); and all-cause mortality (HR 0.92 [95% CI: 0.86–0.99]). The benefits were consistent across all subgroups, including different ejection fraction ranges.

R21.	Class of recommendation	Level of evidence
The use of GLP-1 RAs MAY BE CONSIDERED in individuals with obesity and HF with reduced ejection fraction (HFrEF) for weight reduction, with the aim of improving quality of life and HF-related symptoms, except in NYHA class IV HF.	IIb	B

Summary of evidence (R21):

- In patients with HFrEF, evidence for obesity treatment with GLP-1 RAs is insufficient, and their safety remains debated.

- In the FIGHT study, individuals with recent HFrEF hospitalisation (mean ejection fraction, 27%) randomised to receive liraglutide showed a numerical but nonsignificant increase in HF hospitalisations.⁸⁰

- A *post hoc* analysis of the same study among individuals who received liraglutide for at least one follow-up visit showed significant and safe weight reduction in this population (−1.96 kg, approximately −4.1 pounds). The population had a median age of 61 years, 21% were female, 69% had NYHA class III or IV, and the median ejection fraction was 25% (IQR 19–32%).⁸¹

- In the LIVE study including individuals with chronic HFrEF allocated to the liraglutide group, there was also an increased risk of adverse cardiac events, although only one death and one HF hospitalisation occurred. Notably, the total number of adverse cardiac events was low (12 [10%] with liraglutide vs. 3 [3%] with placebo, p = 0.04).⁸²

- Importantly, neither study (FIGHT or LIVE) aimed to treat HFrEF in individuals with obesity, and liraglutide was not used at obesity treatment doses.

- In a *post hoc* analysis of SELECT including 1,347 individuals with HFrEF (mean BMI 33.4 kg/m²), semaglutide reduced MACE risk by 35% and the composite of CV death and HF hospitalisation/urgent visit by 21%, although the effect on HF hospitalisations alone was not significant (HR 1.08; p = 0.11). Notably, approximately 60% of included individuals had NYHA class II, and individuals with NYHA class IV HF were excluded. Additionally, the adverse event rate during follow-up was low.⁸³

- In a pre-specified analysis of STEP-HFpEF and STEP-HFpEF DM, semaglutide effects on primary outcomes and body weight were similar across three groups based on baseline ejection fraction (45–49%, 50–59%, and ≥60%). Similarly, left ventricular ejection fraction did not influence semaglutide results for the following confirmatory secondary endpoints: 6-minute walk distance (interaction p = 0.19), hierarchical composite endpoint (interaction p = 0.43), and high-sensitivity C-reactive protein.⁸⁴ Despite these results, all GLP-1 RAs, including semaglutide, are associated with a modest increase in heart rate (3–5 bpm).⁸⁵

Important Note 6: Weight loss in patients with HFrEF

There are no RCTs evaluating weight loss in individuals with obesity and HFrEF with NYHA class III–IV in terms of survival improvement.

For these patients, LSM recommendations including caloric restriction should be implemented with careful clinical monitoring. This is due to the potential risk of worsening the catabolic state of the patient, which is often observed in advanced HFrEF and could lead to the development of cachexia and subsequent increased mortality.

Further studies are needed to assess the safety of anti-obesity medications in individuals with HFrEF and NYHA class III or IV, particularly high-potency agents (semaglutide 2.4 mg and tirzepatide 15 mg).

3.2.7. Obesity in Individuals with High Heart Failure Risk

R22.	Class of recommendation	Level of evidence
Use of semaglutide SC (2.4 mg weekly) or tirzepatide (10–15 mg weekly) is RECOMMENDED in individuals with class 3 obesity (BMI ≥ 40 kg/m ²) at high HF risk to improve quality of life and prevent HF-related symptoms	I	C

Summary of evidence (R22):

- Based on expert opinion, this panel recommends weekly use of either semaglutide 2.4 mg SC or tirzepatide 10–15 mg for potential prevention of HF-related outcomes in patients with class 3 obesity or at high HF risk. The panel based its recommendation on studies conducted in patients with established HF^{76,78} as well as on the plausible benefits in this population, given that HF represents a continuous pathophysiological progress through interconnected stages driven by various risk factors, among which obesity plays a central role.¹⁷

R23.	Class of recommendation	Level of evidence
The combination of an SGLT2i and a GLP-1 RA MAY BE CONSIDERED for individuals with obesity, type 2 diabetes, and HF (or at high HF risk) to achieve additional reduction of HFpEF-related outcomes.	IIa	B

Summary of evidence (R23):

- Real-world studies, meta-analyses of RCTs, observational studies, and retrospective studies have indicated a potential additive effect of SGLT2i/GLP-1 RA combination over monotherapy

with either agent. This effect, however, requires confirmation in RCTs. This panel assessed by expert opinion that there is plausibility for additive effects of this combination, as these agents act through different mechanisms, with potential for additive benefit. This panel indicates that the SGLT2i/GLP-1 RA combination should be considered for patients with obesity and HFpEF or at HF risk as it has been associated with greater improvement of HFpEF-related outcomes when compared with monotherapy alone.

- A systematic review with meta-analysis indicates that cardiorenal benefits may be enhanced with combination therapy compared with monotherapy. The study evaluated the cardiorenal effects of combining SGLT2i with GLP-1 RA compared with monotherapy with each agent class in patients with type 2 diabetes. Eligible studies were RCTs and observational studies comparing SGLT2i or GLP-1 RA in combination or as a monotherapy. Five RCTs and 10 *post hoc* observational analyses were identified. Compared with GLP-1 RA monotherapy, combination therapy with SGLT2i and GLP-1 RA was associated with lower risk of HF-related outcomes (RR 0.63, 95% CI: 0.51–0.77, $p < 0.001$) and all-cause mortality (RR 0.66, 95% CI: 0.50–0.88, $p = 0.004$) in patients with type 2 diabetes [86].

- A retrospective real-world study from a Spanish database included 15,549 individuals with type 2 diabetes from 2018 to 2022, with 46% having obesity, 71% having hypertension, 15% having CAD, and 10% established HF. Three groups were established according to the therapy used: 1) SGLT2i monotherapy ($n = 12,029$; mean duration: 14 months), 2) GLP-1 RA monotherapy ($n = 1,071$; mean duration: 17 months), or 3) GLP-1 RA + SGLT2i ($n = 2,449$; mean duration: 14 months). Data were analysed using 1:1 propensity score matching. The median follow-up duration was 19 (8–33) months. Combination therapy versus SGLT2i reduced the risk of HF events (HR 0.69; 95% CI: 0.56–0.87) and all-cause mortality (HR 0.68; 95% CI: 0.54–0.86). Multivariate Cox regression after propensity score matching confirmed the benefit of combination therapy compared with SGLT2i and GLP-1 RA monotherapy. Combined SGLT2i and GLP-1 RA therapy was associated with reduced risk of HF events and all-cause mortality compared with that observed with monotherapy in this population.⁸⁷

3.3. Bariatric Surgery

3.3.1. Obesity Stage 2 and Moderate/High ASCVD Risk or High HF Risk

R24.	Class of recommendation	Level of evidence
Bariatric surgery is RECOMMENDED for individuals with a BMI ≥ 35 kg/m ² at MODERATE or HIGH ASCVD risk or at HIGH HF risk, when patients fail to achieve sustained weight loss and CV risk factor improvement with the available anti-obesity treatment.	I	B

Guidelines

Summary of evidence (R24):

- A systematic review and meta-analysis of 18 observational studies from population databases including over 1.5 million patients evaluated obesity-related disease incidence and overall mortality after a minimum 18-month follow-up in bariatric surgery versus control groups. The analysis identified that bariatric surgery is associated with reduced all-cause mortality (OR 0.62; 95% CI: 0.55–0.69; $p < 0.001$) and CV mortality (OR 0.50; 95% CI: 0.35–0.71; $p < 0.001$). Additionally, there was reduced incidence of type 2 diabetes (OR 0.39; 95% CI: 0.18–0.83), hypertension (OR 0.36; 95% CI: 0.32–0.40), and dyslipidaemia (OR 0.33; 95% CI: 0.14–0.80).⁸⁸

- A longitudinal cohort study evaluated 1,724 patients undergoing bariatric surgery (gastric banding and Roux-en-Y gastric bypass), compared with controls matched for age, BMI, sex, and Framingham score receiving conventional medical treatment and followed up for up to 12 years (median 6.3 years). Surgery was associated with a 42% reduction in MACE risk (HR 0.58; 95% CI: 0.42–0.82; $p = 0.0018$), including myocardial infarction, stroke, and congestive HF. The reduction in congestive HF was particularly marked (HR 0.38; 95% CI: 0.22–0.64; $p = 0.0003$). Improvements in CV risk factors (total cholesterol, HDL cholesterol, and blood pressure) occurred within 1 year and Framingham score improvements within 2 years.⁸⁹

- Concurrently, an observational study evaluated 20,235 individuals with class 2 or 3 obesity and type 2 diabetes from 2005 to 2010 in the United States, where 5,301 underwent bariatric surgery and 14,934 served as controls, matched for age, sex, BMI, and HbA1c. The primary outcome was incidence of acute myocardial infarction, unstable angina, percutaneous coronary intervention, or coronary artery bypass grafting. After 5 years of follow-up, the bariatric surgery group had lower incidence of the primary outcome compared with the non-surgical group: 2.1% vs. 4.3% (HR 0.60, 95% CI: 0.42–0.86), respectively. There was also lower CAD incidence in the surgical group compared with the non-surgical control group: 1.6% vs. 2.8% (HR 0.64, 95% CI: 0.42–0.99).⁹⁰

- The SOS study demonstrated that bariatric surgery is associated with reduced risk of developing HF in individuals with severe obesity versus those with obesity under usual care.⁹¹

- In these studies, the effects of bariatric surgery on CV event reduction were observed progressively following normalisation of metabolic parameters including blood pressure, lipid profile, and glycaemic control. MACE reduction cannot be attributed to direct or immediate surgical effects on the CV system, as CV risk factor improvements occurred after sustained weight loss, and comparisons were made with less effective anti-obesity pharmacotherapy treatment. This panel considers that, in the absence of specific RCTs, the indication of bariatric surgery for CV event prevention should be considered based on its long-term benefits in improving risk factors, particularly in patients at moderate or high CV risk who either lack access to or do not achieve a sustained response with currently available anti-obesity therapies.

3.3.2. Obesity Stage 2 and Heart Failure

R25.	Class of recommendation	Level of evidence
Bariatric surgery MAY BE CONSIDERED cautiously, according to surgical risk, in individuals with established HF and a BMI ≥ 35 kg/m ² to promote weight loss and improve risk factors and HF-related symptoms.	IIb	B

Summary of evidence (R25):

- Although severe HF or marked systolic dysfunction may be considered as a contraindication to bariatric surgery, emerging evidence has indicated that the procedure may be appropriate for select patients with obesity and stable HF.

- A systematic review with meta-analysis demonstrated that bariatric surgery is associated with reduced HF-related hospitalisations, as well as improvements in left ventricular ejection fraction and NYHA functional class.⁹²

- Bariatric surgery has also shown benefits in reducing CV risk factors and improving cardiac function, including reversal of cardiac remodelling and improvements in both systolic and diastolic performance.⁹³

Important Note 7: Bariatric surgery in patients with HF

The long-term safety and efficacy of bariatric surgery in patients with HF remain insufficiently established. Further prospective studies are needed to identify patients who can be safely referred for this intervention. The decision to proceed with bariatric surgery in patients with HF should be individualised, considering the patient's clinical status, comorbid conditions, and ability to tolerate the procedure. A multidisciplinary approach is strongly recommended to optimise outcomes and minimise associated risks.

Important Note 8: Obesity management in elderly

- In the context of the elderly population, the therapeutic approach should be individualized, since there is a higher prevalence of sarcopenic obesity, frailty, multiple comorbidities, and polypharmacy. All these factors must be considered, especially regarding the establishment of therapeutic weight loss goals.

The recommendations of this guideline were based on the best available clinical evidence (well-designed ancillary studies and randomized controlled trials), in which people of advanced age (over 75 years) are underrepresented. Nevertheless, in the post hoc sub-analysis of GLP-1 RA cardiovascular outcomes trials, significant reduction in MACE was observed across age subgroups.⁹⁴

Important Note 9: Obesity management in the context of Brazilian public health system

- Although obesity is highly prevalent in Brazil, it has often been overlooked within the broader context of non-communicable diseases (NCDs) related to cardiovascular disease. The CV risk stratification proposed in the guideline provides a rationale for better decisions in the choice of anti-obesity treatment.
- Recognizing that cardiovascular risk in people with obesity occurs on a continuum, the approach based on CV risk classification can assist policymakers in decision-making and implementation of treatments for populations at higher CV risk.

Conclusion

Considering the increasing incidence of obesity and its well-established association with CVD and related outcomes, CV risk assessment must be a central component in obesity treatment planning. This guideline, developed through a collaboration among five leading Brazilian medical societies, addresses this critical need by providing evidence-based strategies for the treatment of obesity and prevention of CVD. Importantly, the guideline considers the specific public health context of the Brazilian population, offering recommendations that carefully considers the risks and benefits of each therapeutic approach. **Subsistir por:** We acknowledge that implementing these recommendations for the Brazilian population presents a great challenge. Given there are currently no anti-obesity pharmacological therapies available in the Unified Health System (SUS), it is essential to prioritize interventions with proven efficacy to reduce cardiovascular events in the

groups with highest CV risk. This approach may support policymakers in cost-effective resource plans to control obesity and reduce associated complications.

Supplement

SCREENING FOR RISK FACTORS FOR ASCVD AND HF

Hypertension

For the screening and diagnosis of hypertension in adults, a systolic pressure ≥ 140 mmHg and/or diastolic ≥ 90 mmHg, confirmed in two or more measurements on separate occasions should be used as the diagnostic criterion. Individuals with systolic pressure between 130-139 mmHg and/or diastolic pressure **85-89** mmHg should be considered as having pre-hypertension.

Dyslipidemia

Universal screening for hypercholesterolaemia is recommended starting at age 9 and. In cases with a family history of hypercholesterolaemia, screening should begin after age of **2**. Assessment should include measurements of both cholesterol and triglyceride levels.

Type 2 diabetes

All individuals who are overweight or obese should be screened for type 2 diabetes beginning at age 35, using both fasting blood glucose and HbA1c tests. Before the age of 35, screening is mandatory if at least one of the additional risk factors for diabetes is present (see Table 1). Screening may also be considered before the age of 35, on a case-by-case basis, at the discretion of the healthcare provider and in consultation with the patient.

TABLE 1. RISK FACTORS THAT INDICATE SCREENING FOR TYPE 2 DIABETES IN PATIENTS WITH OVERWEIGHT OR OBESITY

- Previously elevated fasting glucose (>100 mg/dL).
- Previous gestational diabetes.
- Mother of a large-for-gestational-age newborn.
- Family history of type 2 diabetes in a first-degree relative.
- History of clinical CVD (ACS/AMI, chronic CAD, ischemic stroke or TIA, arterial revascularisation), or subclinical CVD (CAC >0 or presence of plaque in the carotid artery).
- Presence of hypertension, treated or not.
- HDL <35 mg/dL.
- Triglycerides > 250 mg/dL.
- Polycystic ovary syndrome.
- Presence of acanthosis nigricans.
- Sedentary lifestyle.
- Metabolic steatotic liver disease (MASLD or MASH).
- FINDRISC high or very high.

References

- World Obesity Federation. World Obesity Atlas 2025 [Internet]. London: World Obesity Federation; 2025 [cited 2025 Jul 15]. Available from: <https://data.worldobesity.org/publications/?cat=23>.
- Tan SCW, Zheng BB, Tang ML, Chu H, Zhao YT, Weng C. Global Burden of Cardiovascular Diseases and its Risk Factors, 1990-2021: A Systematic Analysis for the Global Burden of Disease Study 2021. *QJM*. 2025:hcaf022. doi: 10.1093/qjmed/hcaf022.
- Koskinas KC, van Craenenbroeck EM, Antoniadou C, Blüher M, Gorter TM, Hanssen H, et al. Obesity and Cardiovascular Disease: An ESC Clinical Consensus Statement. *Eur Heart J*. 2024;45(38):4063-98. doi: 10.1093/eurheartj/ehae508.
- Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. *Circulation*. 2021;143(21):e984-e1010. doi: 10.1161/CIR.0000000000000973.
- Cerhan JR, Moore SC, Jacobs EJ, Kitahara CM, Rosenberg PS, Adami HO, et al. A Pooled Analysis of Waist Circumference and Mortality in 650,000 Adults. *Mayo Clin Proc*. 2014;89(3):335-45. doi: 10.1016/j.mayocp.2013.11.011.
- Carmienie S, Freitag MH, Pischon T, Schlattmann P, Fankhaenel T, Goebel H, et al. General and Abdominal Obesity Parameters and their Combination in Relation to Mortality: A Systematic Review and Meta-Regression Analysis. *Eur J Clin Nutr*. 2013;67(6):573-85. doi: 10.1038/ejcn.2013.61.
- Benn M, Marott SCW, Tybjaerg-Hansen A, Nordestgaard BG. Obesity Increases Heart Failure Incidence and Mortality: Observational and Mendelian Randomization Studies Totalling Over 1 Million Individuals. *Cardiovasc Res*. 2023;118(18):3576-85. doi: 10.1093/cvr/cvab368.
- Silva WS Jr. Under New Criteria for Clinical Obesity, is Metabolic Obesity with Normal Body Weight Finally a Legitimate Disease Phenotype? *Diab Technol Obes Med*. 2025;1(1):62-70. doi: 10.1089/dtom.2025.0015.
- Rubino F, Batterham RL, Koch M, Mingrone G, le Roux CW, Farooqi IS, et al. Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity. *Lancet Diabetes Endocrinol*. 2023;11(4):226-8. doi: 10.1016/S2213-8587(23)00058-X.
- Busetto L, Dicker D, Frühbeck G, Halford JCG, Sbraccia P, Yumuk V, et al. A New Framework for the Diagnosis, Staging and Management of Obesity in Adults. *Nat Med*. 2024;30(9):2395-9. doi: 10.1038/s41591-024-03095-3.
- Liu XY, Ge SY, Liu CA, Yin B, Bu ZT, Zheng X, et al. Validation of the 2024 European Association for the Study of Obesity Diagnostic Criteria: A Comprehensive Assessment of Obesity-Related Mortality Risks. *Diabetes Obes Metab*. 2025;27(5):2405-17. doi: 10.1111/dom.16236.
- Godoy-Matos AF, Valério CM, Silva WS Jr, Araujo-Neto JM, Sposito AC, Suassuna JHR. CARDIAL-MS (Cardio-Renal-Diabetes-Liver-Metabolic Syndrome): A New Proposition for an Integrated Multisystem Metabolic Disease. *Diabetol Metab Syndr*. 2025;17(1):218. doi: 10.1186/s13098-025-01796-4.
- Khan SS, Matsushita K, Sang Y, Ballew SH, Grams ME, Surapaneni A, et al. Development and Validation of the American Heart Association's PREVENT Equations. *Circulation*. 2024;149(6):430-49. doi: 10.1161/CIRCULATIONAHA.123.067626.
- Arici M, Assaad-Khalil SH, Bertolucci MC, Choo J, Lee YJ, Madero M, et al. Results from a Cross-Specialty Consensus on Optimal Management of Patients with Chronic Kidney Disease (CKD): From Screening to Complications. *BMJ Open*. 2024;14(3):e080891. doi: 10.1136/bmjopen-2023-080891.
- Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement from the American Heart Association. *Circulation*. 2023;148(24):1982-2004. doi: 10.1161/CIR.0000000000001191.
- American Heart Association. PREVENT Online Calculator [Internet]. Dallas: American Heart Association; 2025 [cited 2025 Jul 15]. Available from: <https://professional.heart.org/en/guidelines-and-statements/prevent-calculator>.
- Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. *J Card Fail*. 2021;S1071-9164(21)00050-6. doi: 10.1016/j.cardfail.2021.01.022.
- Reddy YNV, Carter RE, Sundaram V, Kaye DM, Handoko ML, Tedford RJ, et al. An Evidence-Based Screening Tool for Heart Failure with Preserved Ejection Fraction: The HFpEF-ABA Score. *Nat Med*. 2024;30(8):2258-64. doi: 10.1038/s41591-024-03140-1.
- Wang X, Ouyang Y, Wang Z, Zhao G, Liu L, Bi Y. Obstructive Sleep Apnea and Risk of Cardiovascular Disease and All-Cause Mortality: A Meta-Analysis of Prospective Cohort Studies. *Int J Cardiol*. 2013;169(3):207-14. doi: 10.1016/j.ijcard.2013.08.088.
- Zhang X, Fan J, Guo Y, Zhou J, Chen F, Jin Z, et al. Association between Obstructive Sleep Apnoea Syndrome and the Risk of Cardiovascular Diseases: An Updated Systematic Review and Dose-Response Meta-Analysis. *Sleep Med*. 2020;71:39-46. doi: 10.1016/j.sleep.2020.03.011.
- Reddy YNV, Tada A, Obokata M, Carter RE, Kaye DM, Handoko ML, et al. Evidence-Based Application of Natriuretic Peptides in the Evaluation of Chronic Heart Failure with Preserved Ejection Fraction in the Ambulatory Outpatient Setting. *Circulation*. 2025;151(14):976-89. doi: 10.1161/CIRCULATIONAHA.124.072156.
- Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. *N Engl J Med*. 2002;346(6):393-403. doi: 10.1056/NEJMoa012512.
- Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. *N Engl J Med*. 2013;369(2):145-54. doi: 10.1056/NEJMoa1212914.
- Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals with Type 2 Diabetes. *Diabetes Care*. 2011;34(7):1481-6. doi: 10.2337/dc10-2415.
- Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, et al. Morbidity and Mortality after Lifestyle Intervention for People with Impaired Glucose Tolerance: 30-Year Results of the Da Qing Diabetes Prevention Outcome Study. *Lancet Diabetes Endocrinol*. 2019;7(6):452-61. doi: 10.1016/S2213-8587(19)30093-2.
- Look AHEAD Research Group. Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults with Type 2 Diabetes and Overweight/Obesity: Results from the Look AHEAD Study. *Diabetes Care*. 2022;45(5):1252-9. doi: 10.2337/dc21-1805.
- Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, Clark JM, et al. Association of the Magnitude of Weight Loss and Changes in Physical Fitness with Long-Term Cardiovascular Disease Outcomes in Overweight or Obese People with Type 2 Diabetes: A Post-Hoc Analysis of the Look AHEAD Randomised Clinical Trial. *Lancet Diabetes Endocrinol*. 2016;4(11):913-21. doi: 10.1016/S2213-8587(16)30162-0.
- Sattar N, Lee MMY. Estimating Direct Tissue Effects versus Weight Loss Effects of Incretin-Based Drugs for Obesity on Various Chronic Conditions. *Lancet Diabetes Endocrinol*. 2025;13(4):347-54. doi: 10.1016/S2213-8587(24)00363-2.
- Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric Surgery and Long-Term Cardiovascular Events. *JAMA*. 2012;307(1):56-65. doi: 10.1001/jama.2011.1914.

30. Halpern B, Mancini MC, Melo ME, Lamounier RN, Moreira RO, Carra MK, et al. Proposal of an Obesity Classification Based on Weight History: An Official Document by the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society for the Study of Obesity and Metabolic Syndrome (ABESO). *Arch Endocrinol Metab.* 2022;66(2):139-51. doi: 10.20945/2359-3997000000465.
31. Nalliah CJ, Sanders P, Kottkamp H, Kalman JM. The Role of Obesity in Atrial Fibrillation. *Eur Heart J.* 2016;37(20):1565-72. doi: 10.1093/eurheartj/ehv486.
32. Abed HS, Wittert GA, Leong DP, Shirazi MG, Bahrami B, Middeldorp ME, et al. Effect of Weight Reduction and Cardiometabolic Risk Factor Management on Symptom Burden and Severity in Patients with Atrial Fibrillation: A Randomized Clinical Trial. *JAMA.* 2013;310(19):2050-60. doi: 10.1001/jama.2013.280521.
33. Aldaas OM, Lupercio F, Han FT, Hoffmayer KS, Krummen D, Ho G, et al. Meta-Analysis of Effect of Modest ($\geq 10\%$) Weight Loss in Management of Overweight and Obese Patients with Atrial Fibrillation. *Am J Cardiol.* 2019;124(10):1568-74. doi: 10.1016/j.amjcard.2019.08.009.
34. Akhtar KH, Jafry AH, Beard C, Nasir YM, Agarwal S, Khan J, et al. The Effect of Weight Loss on Recurrence of Atrial Fibrillation after Catheter Ablation: A Systematic Review and Meta-Analysis. *J Cardiovasc Electrophysiol.* 2023;34(12):2514-26. doi: 10.1111/jce.16090.
35. Jamaly S, Carlsson L, Peltonen M, Jacobson P, Sjöström L, Karason K. Bariatric Surgery and the Risk of New-Onset Atrial Fibrillation in Swedish Obese Subjects. *J Am Coll Cardiol.* 2016;68(23):2497-504. doi: 10.1016/j.jacc.2016.09.940.
36. Wadden TA, Tronieri JS, Butryn ML. Lifestyle Modification Approaches for the Treatment of Obesity in Adults. *Am Psychol.* 2020;75(2):235-51. doi: 10.1037/amp0000517.
37. Bray GA, Ryan DH. Evidence-Based Weight Loss Interventions: Individualized Treatment Options to Maximize Patient Outcomes. *Diabetes Obes Metab.* 2021;23(Suppl 1):50-62. doi: 10.1111/dom.14200.
38. Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Phelan S, Cato RK, et al. Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity. *N Engl J Med.* 2005;353(20):2111-20. doi: 10.1056/NEJMoa050156.
39. Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. *N Engl J Med.* 2021;384(18):1719-30. doi: 10.1056/NEJMoa2028198.
40. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight Loss with Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial. *Obesity.* 2011;19(1):110-20. doi: 10.1038/oby.2010.147.
41. Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults with Overweight or Obesity: The STEP 3 Randomized Clinical Trial. *JAMA.* 2021;325(14):1403-13. doi: 10.1001/jama.2021.1831.
42. Wadden TA, Chao AM, Machineni S, Kushner R, Ard J, Srivastava G, et al. Tirzepatide after Intensive Lifestyle Intervention in Adults with Overweight or Obesity: The SURMOUNT-3 Phase 3 Trial. *Nat Med.* 2023;29(11):2909-18. doi: 10.1038/s41591-023-02597-w.
43. Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, et al. The Role of Lifestyle Modification with Second-Generation Anti-Obesity Medications: Comparisons, Questions, and Clinical Opportunities. *Curr Obes Rep.* 2023;12(4):453-73. doi: 10.1007/s13679-023-00534-z.
44. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N Engl J Med.* 2018;378(25):e34. doi: 10.1056/NEJMoa1800389.
45. Shan Z, Wang F, Li Y, Baden MY, Bhupathiraju SN, Wang DD, et al. Healthy Eating Patterns and Risk of Total and Cause-Specific Mortality. *JAMA Intern Med.* 2023;183(2):142-53. doi: 10.1001/jamainternmed.2022.6117.
46. Pepe RB, Lottenberg AM, Fujiwara CTH, Beyruti M, Cintra DE, Machado RM, et al. Position Statement on Nutrition Therapy for Overweight and Obesity: Nutrition Department of the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO-2022). *Diabetol Metab Syndr.* 2023;15(1):124. doi: 10.1186/s13098-023-01037-6.
47. Nilson EAF, Delpino FM, Batis C, Machado PP, Moubarac JC, Cediel G, et al. Premature Mortality Attributable to Ultraprocessed Food Consumption in 8 Countries. *Am J Prev Med.* 2025;68(6):1091-9. doi: 10.1016/j.amepre.2025.02.018.
48. le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, van Gaal L, et al. 3 Years of Liraglutide versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals with Prediabetes: A Randomised, Double-Blind Trial. *Lancet.* 2017;389(10077):1399-409. doi: 10.1016/S0140-6736(17)30069-7.
49. Davies MJ, Aronne LJ, Caterson ID, Thomsen AB, Jacobsen PB, Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Adults with Overweight or Obesity: A Post Hoc Analysis from SCALE Randomized Controlled Trials. *Diabetes Obes Metab.* 2018;20(3):734-9. doi: 10.1111/dom.13125.
50. Wilding JPH, Batterham RL, Calanna S, Davies M, van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N Engl J Med.* 2021;384(11):989-1002. doi: 10.1056/NEJMoa2032183.
51. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. *N Engl J Med.* 2025;392(10):958-71. doi: 10.1056/NEJMoa2410819.
52. Lazzaroni E, Ben Nasr M, Loretelli C, Pastore I, Plebani L, Lunati ME, et al. Anti-Diabetic Drugs and Weight Loss in Patients with Type 2 Diabetes. *Pharmacol Res.* 2021;171:105782. doi: 10.1016/j.phrs.2021.105782.
53. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study: A Randomized Study of Orlistat as an Adjunct to Lifestyle Changes for the Prevention of Type 2 Diabetes in Obese Patients. *Diabetes Care.* 2004;27(1):155-61. doi: 10.2337/diacare.27.1.155.
54. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of Pharmacological Treatments for Obesity with Weight Loss and Adverse Events: A Systematic Review and Meta-Analysis. *JAMA.* 2016;315(22):2424-34. doi: 10.1001/jama.2016.7602.
55. Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland JJ, et al. Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-Analysis. *Gastroenterology.* 2018;154(5):1309-19.e7. doi: 10.1053/j.gastro.2017.12.024.
56. Nissen SE, Wolski KE, Prcela L, Wadden T, Buse JB, Bakris G, et al. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients with Cardiovascular Risk Factors: A Randomized Clinical Trial. *JAMA.* 2016;315(10):990-1004. doi: 10.1001/jama.2016.1558.
57. Sposito AC, Bonilha I, Luchiarri B, Benchimol A, Hohl A, Moura F, et al. Cardiovascular Safety of Naltrexone and Bupropion Therapy: Systematic Review and Meta-Analyses. *Obes Rev.* 2021;22(6):e13224. doi: 10.1111/obr.13224.
58. Moreira RO, Valerio CM, Hohl A, Moulin C, Moura F, Trujillo FR, et al. Pharmacologic Treatment of Obesity in Adults and its Impact on Comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (ABESO) and the Brazilian Society of Endocrinology and Metabolism (SBEM). *Arch Endocrinol Metab.* 2024;68:e240422. doi: 10.20945/2359-4292-2024-0422.
59. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023;389(24):2221-32. doi: 10.1056/NEJMoa2307563.

Guidelines

60. James WP, Caterson ID, Coutinho W, Finer N, van Gaal LF, Maggioni AP, et al. Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects. *N Engl J Med*. 2010;363(10):905-17. doi: 10.1056/NEJMoa1003114.
61. Lee M, Ghouri N, Misra A, Kang YM, Ruttler MK, Gerstein HC, et al. Comparative Efficacy of Glucagon-Like Peptide 1 Receptor Agonists for Cardiovascular Outcomes in Asian versus White Populations: Systematic Review and Meta-analysis of Randomized Trials of Populations with or Without Type 2 Diabetes and/or Overweight or Obesity. *Diabetes Care*. 2025;48(3):489-93. doi: 10.2337/dc24-1533.
62. Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Trials. *Lancet Diabetes Endocrinol*. 2021;9(10):653-62. doi: 10.1016/S2213-8587(21)00203-5.
63. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-Glucose Cotransporter Protein-2 (SGLT-2) Inhibitors and Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Type 2 Diabetes: Systematic Review and Network Meta-Analysis of Randomised Controlled Trials. *BMJ*. 2021;372:m4573. doi: 10.1136/bmj.m4573.
64. McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. *N Engl J Med*. 2025;392(20):2001-12. doi: 10.1056/NEJMoa2501006.
65. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. *N Engl J Med*. 2024;391(2):109-21. doi: 10.1056/NEJMoa2403347.
66. Tuomilehto HP, Seppä JM, Partinen MM, Peltonen M, Gylling H, Tuomilehto JO, et al. Lifestyle Intervention with Weight Reduction: First-Line Treatment in Mild Obstructive Sleep Apnea. *Am J Respir Crit Care Med*. 2009;179(4):320-7. doi: 10.1164/rccm.200805-669OC.
67. Foster GD, Borradaile KE, Sanders MH, Millman R, Zammit G, Newman AB, et al. A randomized Study on the Effect of Weight Loss on Obstructive Sleep Apnea Among Obese Patients with Type 2 Diabetes: the Sleep AHEAD Study. *Arch Intern Med*. 2009;169(17):1619-26. doi: 10.1001/archinternmed.2009.266.
68. Carneiro-Barrera A, Amaro-Gahete FJ, Guillén-Riquelme A, Jurado-Fasoli L, Sáez-Roca G, Martín-Carrasco C, et al. Effect of an Interdisciplinary Weight Loss and Lifestyle Intervention on Obstructive Sleep Apnea Severity: The INTERAPNEA Randomized Clinical Trial. *JAMA Netw Open*. 2022;5(4):e228212. doi: 10.1001/jamanetworkopen.2022.8212.
69. Johansson K, Neovius M, Lagerros YT, Harlid R, Rössner S, Granath F, et al. Effect of a Very Low Energy Diet on Moderate and Severe Obstructive Sleep Apnoea in Obese Men: A Randomised Controlled Trial. *BMJ*. 2009;339:b4609. doi: 10.1136/bmj.b4609.
70. Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of Liraglutide 3.0 mg in Individuals with Obesity and Moderate or Severe Obstructive Sleep Apnea: The SCALE Sleep Apnea Randomized Clinical Trial. *Int J Obes*. 2016;40(8):1310-9. doi: 10.1038/ijo.2016.52.
71. Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *N Engl J Med*. 2024;391(13):1193-205. doi: 10.1056/NEJMoa2404881.
72. U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea [Internet]. [cited 2025 Jul 15]. Silver Spring: Food and Drug Administration; 2024 Available from: <https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea>.
73. Chen B, Drager LF, Peker Y, Vgontzas AN, Phillips CL, Hoyos CM, et al. Effect of Continuous Positive Airway Pressure on Weight and Local Adiposity in Adults with Obstructive Sleep Apnea: A Meta-Analysis. *Ann Am Thorac Soc*. 2021;18(10):1717-27. doi: 10.1513/AnnalsATS.202101-060OC.
74. Chi M, Nie Y, Su Y, Wang N, Li A, Ma T, et al. Effects of Weight Loss in Heart Failure Patients with Overweight and Obesity: A Systematic Review and Meta-Analysis. *Eur J Prev Cardiol*. 2023;30(17):1906-21. doi: 10.1093/eurjpc/zwad284.
75. Mahajan R, Stokes M, Elliott A, Munawar DA, Khokhar KB, Thiyagarajah A, et al. Complex Interaction of Obesity, Intentional Weight Loss and Heart Failure: A Systematic Review and Meta-Analysis. *Heart*. 2020;106(1):58-68. doi: 10.1136/heartjnl-2019-314770.
76. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med*. 2023;389(12):1069-84. doi: 10.1056/NEJMoa2306963.
77. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Christensen L, Davies M, et al. Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients with Obesity HFpEF Phenotype. *JACC Heart Fail*. 2023;11(8 Pt 1):1000-10. doi: 10.1016/j.jchf.2023.05.010.
78. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. *N Engl J Med*. 2025;392(5):427-37. doi: 10.1056/NEJMoa2410027.
79. Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, Hernandez AF, et al. SGLT-2 Inhibitors in Patients with Heart Failure: A Comprehensive Meta-Analysis of Five Randomised Controlled Trials. *Lancet*. 2022;400(10354):757-67. doi: 10.1016/S0140-6736(22)01429-5.
80. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of Liraglutide on Clinical Stability among Patients with Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. *JAMA*. 2016;316(5):500-8. doi: 10.1001/jama.2016.10260.
81. Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, et al. Liraglutide and Weight Loss among Patients with Advanced Heart Failure and a Reduced Ejection Fraction: Insights from the FIGHT Trial. *ESC Heart Fail*. 2018;5(6):1035-43. doi: 10.1002/ehf2.12334.
82. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and without Diabetes (LIVE)-a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial. *Eur J Heart Fail*. 2017;19(1):69-77. doi: 10.1002/ehfj.657.
83. Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, et al. Semaglutide and Cardiovascular Outcomes in Patients with Obesity and Prevalent Heart Failure: A Prespecified Analysis of the SELECT Trial. *Lancet*. 2024;404(10454):773-86. doi: 10.1016/S0140-6736(24)01498-3.
84. Butler J, Abildstrøm SZ, Borlaug BA, Davies MJ, Kitzman DW, Petrie MC, et al. Semaglutide in Patients with Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. *J Am Coll Cardiol*. 2023;82(22):2087-96. doi: 10.1016/j.jacc.2023.09.811.
85. Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 Receptor Agonists on Blood Pressure, Heart Rate and Hypertension among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. *Diabetes Res Clin Pract*. 2015;110(1):26-37. doi: 10.1016/j.diabetes.2015.07.015.
86. Zhang M, Lin C, Cai X, Jiao R, Bai S, Li Z, et al. One or Two? Comparison of the Cardiorenal effects between Combination Therapy and Monotherapy with SGLT2i or GLP1RA. *Diabetes Obes Metab*. 2025;27(2):806-15. doi: 10.1111/dom.16078.
87. García-Vega D, Cinza-Sanjurjo S, Eiras S, González-Juanatey JR. Combined Sodium-Glucose-Transporters Inhibitors and Glucagon-Like-Peptide Receptor Agonist Compared with Monotherapy Improves Long-Term Survival: A Real-World Registry. *Am J Med*. 2024;137(8):761-9.e1. doi: 10.1016/j.amjmed.2024.04.032.
88. Wiggins T, Guidozzi N, Welbourn R, Ahmed AR, Markar SR. Association of Bariatric Surgery with All-Cause Mortality and Incidence of Obesity-Related Disease at a Population Level: A Systematic Review and Meta-Analysis. *PLoS Med*. 2020;17(7):e1003206. doi: 10.1371/journal.pmed.1003206.
89. Benotti PN, Wood GC, Carey DJ, Mehra VC, Mirshahi T, Lent MR, et al. Gastric Bypass Surgery Produces a Durable Reduction in Cardiovascular Disease Risk Factors and Reduces the Long-Term Risks of Congestive Heart Failure. *J Am Heart Assoc*. 2017;6(5):e005126. doi: 10.1161/JAHA.116.005126.

90. Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O'Connor PJ, et al. Association between Bariatric Surgery and Macrovascular Disease Outcomes in Patients with Type 2 Diabetes and Severe Obesity. *JAMA*. 2018;320(15):1570-82. doi: 10.1001/jama.2018.14619.
91. Jamaly S, Carlsson L, Peltonen M, Jacobson P, Karason K. Surgical Obesity Treatment and the Risk of Heart Failure. *Eur Heart J*. 2019;40(26):2131-8. doi: 10.1093/eurheartj/ehz295.
92. Esparham A, Mehri A, Hadian H, Taheri M, Moghadam HA, Kalantari A, et al. The Effect of Bariatric Surgery on Patients with Heart Failure: A Systematic Review and Meta-Analysis. *Obes Surg*. 2023;33(12):4125-36. doi: 10.1007/s11695-023-06898-4.
93. Kindel TL, Higgins RM, Lak K, Gould J, Kreuziger LB, Mohammed A, et al. Bariatric Surgery in Patients with Advanced Heart Failure: A Proposed Multi-Disciplinary pathway for Surgical Care in Medically Complex Patients. *Surgery*. 2021;170(3):659-63. doi: 10.1016/j.surg.2021.04.036.
94. Bain SC, Belmar N, Hoff ST, Husain M, Rasmussen S, Vilsbøll T, et al. Cardiovascular, Metabolic, and Safety Outcomes with Semaglutide by Baseline Age: Post Hoc Analysis of SUSTAIN 6 and PIONEER 6. *Diabetes Ther*. 2025;16(1):15-28. doi: 10.1007/s13300-024-01659-7.



This is an open-access article distributed under the terms of the Creative Commons Attribution License